Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
drug manufacturing
Pharma
FDA rejects Hengrui, Elevar's PD-1 cancer drug combo—again
In handing down the second rejection, the FDA again raised manufacturing issues that required responses from Hengrui.
Angus Liu
Mar 21, 2025 3:25pm
Granules hit with FDA warning letter over production woes
Mar 5, 2025 8:38am
Pfizer could shift production to US to help manage tariffs: CEO
Mar 3, 2025 4:20pm
Merck nabs $30M commitment from Delaware for potential facility
Feb 27, 2025 3:59pm
FDA hits Piramal with 6-observation Form 483 at India API plant
Feb 26, 2025 10:22am
Lilly swells manufacturing outlay to more than $50B since 2020
Feb 26, 2025 9:30am
